Answers are grounded in this paper and cite their sources.
Experimental analysis shows improved insulin sensitivity in obesity, suggesting a novel therapeutic method.
The chitosan-conjugated hybrid polymer-lipid nanocarrier significantly enhanced systemic exposure and metabolic efficacy of FA, demonstrating sustained antioxidant-mediated improvement in insulin sensitivity and lipid homeostasis. This nano-enabled strategy represents a promising oral therapeutic platform for obesity-associated metabolic dysfunction.
No takes yet. Share an insight, caveat, or question.
Meshram et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: